Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.
To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this – https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments:
Type of Product
API
FDF
Type of Biologic
- Proteins
- Enzymes
- Growth Hormones
- Antibody based Drugs
- Others (plasmid DNA, probiotics, microbiome-based biologics)
- Type of Microbial Expression System
- Bacteria
- Yeast
- Others (Algae and fungi)
Scale of Operation
Commercial
Preclinical / Clinical
Type of End User
Small Companies
Mid-sized Companies
Large / Very Large Companies
Key Geographical Regions
North America
Europe
Asia Pacific
Middle East and North Africa
Latin America
The Microbial Contract Biomanufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
- AGC Biologics
- Aldevron
- BioVectra
- EirGenix
- Etinpro
- Eurogentec
- Northway Biotechpharma
- Ology Bioservices
- Porton Biopharma
- Stelis Biopharma
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company Competitiveness Analysis
6. Company Profiles
7. Recent Partnerships
8. Recent Expansions
9. Microbial fermentation technology platforms
10. Assessment of Relative Competition and Growth
11. Make versus Buy Decision Making Framework
12. Big Pharma Initiatives in Microbial Biomanufacturing
13. Case study: comparison of small molecule and large
14. Market Sizing and Opportunity Analysis
15. Impact of covid-19 pandemic on microbial contract biomanufacturing market
16. Swot Analysis
17. Conclusion Appendix 3: List of Companies and Organizations
18. Interview Transcripts
19. Appendix 1: Tabulated Data
20. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
